Legal
Important Safety Information & Consumer Rights
Effective Date: November 18, 2026
Last Updated: November 18, 2026
Read this important safety information before using any medication. This page provides general safety information about medications that may be prescribed through SurpassMD. It is not a substitute for the advice of your Provider or the information provided with your medication. Always talk to your Provider about the benefits and risks of any treatment, and disclose your complete medical history. If you are experiencing a medical emergency, call 911.
1. Compounded Medications Are Not FDA-Approved
Certain medications offered through the Services are compounded. Compounded medications are prepared by a licensed pharmacy for an individual patient pursuant to a prescription. They are not approved by the FDA, and the FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. Whether a particular compounded medication may lawfully be dispensed to you depends on the specific pharmacy, your prescription, your individual clinical need, and applicable federal and state compounding requirements, including Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounded medications are not generic equivalents of, and have not been determined to be therapeutically equivalent to, any FDA-approved product, and may differ in appearance, strength, or inactive ingredients.
2. Important Safety Information: Compounded Semaglutide
Important Ingredient Warning: Risk of Thyroid C-Cell Tumors
Semaglutide causes thyroid C-cell tumors in rodents. It is not known whether semaglutide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the potential risk of MTC and the symptoms of thyroid tumors, such as a mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Do not use semaglutide if you
have or have had MTC or MEN 2; are allergic to semaglutide or any of its ingredients; or are pregnant or planning to become pregnant. Semaglutide may cause fetal harm; discontinue use at least two months before a planned pregnancy.
Warnings and precautions
Semaglutide may cause inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially when used with insulin or a sulfonylurea), acute kidney injury (often related to dehydration from nausea, vomiting, or diarrhea), serious allergic reactions, and diabetic retinopathy complications. Stop use and seek care for severe abdominal pain or signs of an allergic reaction. Tell your Provider about all medical conditions and medications, including any history of depression or mood changes.
Common side effects
The most common side effects include nausea, vomiting, diarrhea, abdominal pain, constipation, indigestion, and fatigue. This is not a complete list. Report side effects to your Provider and to the FDA at 1-800-FDA-1088.
3. Important Safety Information: Compounded Tirzepatide
Important Ingredient Warning: Risk of Thyroid C-Cell Tumors
Tirzepatide causes thyroid C-cell tumors in rats. It is not known whether tirzepatide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the potential risk of MTC and the symptoms of thyroid tumors, such as a mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Do not use tirzepatide if you
have or have had MTC or MEN 2; are allergic to tirzepatide or any of its ingredients; or are pregnant or planning to become pregnant. Tirzepatide may cause fetal harm; discontinue use before a planned pregnancy.
Warnings and precautions
Tirzepatide may cause pancreatitis, gallbladder problems, low blood sugar (especially with insulin or a sulfonylurea), acute kidney injury, serious allergic reactions, and diabetic retinopathy complications. Tirzepatide may also reduce the effectiveness of oral contraceptives; talk to your Provider about switching to a non-oral contraceptive, or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Stop use and seek care for severe abdominal pain or signs of an allergic reaction.
Common side effects
The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and decreased appetite. This is not a complete list. Report side effects to your Provider and to the FDA at 1-800-FDA-1088.
4. Compounded GLP-1 Dosing Safety
Compounded GLP-1 medications can come in different concentrations and presentations, and dosing errors are a known risk that the FDA has warned about. A dose may be written in milligrams (mg) while a syringe is marked in units or milliliters, which can lead to taking far more than intended. To use these medications safely: confirm the concentration and your exact dose with your Provider; never assume two products are dosed the same way; measure carefully and do not change your dose or titration schedule on your own; use only the dosing device you are given or directed to use; and follow the dispensing Pharmacy’s product-specific storage instructions, including refrigeration when required and protection from freezing. If a medication has been left at room temperature too long, frozen, or otherwise exposed to improper temperatures, do not use it and contact us. If you are unsure how to measure or inject a dose, stop and ask your Provider before proceeding.
For compounded sterile GLP-1 vials used for multiple doses, FDA currently recommends discarding the vial within 28 days after first use even if medication remains or a compounder gives a longer period. Use a new sterile needle and syringe for each dose. Contact your Provider or Pharmacy if the supplied quantity or instructions conflict with this guidance; do not extend use on your own.
For current federal safety information, see FDA’s concerns with unapproved GLP-1 drugs.
5. Oral Semaglutide and Formulation-Specific Instructions
If prescribed an oral, sublingual, or other non-injectable compounded formulation, review the exact formulation and instructions with your Provider and dispensing Pharmacy. Compounded oral products are not interchangeable with FDA-approved semaglutide tablets or injectable products. Do not substitute doses or assume that administration, absorption, effectiveness, storage, or other instructions are the same.
Follow the directions for the product actually dispensed. Ask your Provider or Pharmacy about administration, interactions with other medicines, food or drink restrictions, and missed doses. The general semaglutide warnings on this page are not a complete safety assessment of a particular compounded formulation.
6. Trademarks and Affiliation
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. SurpassMD and the Providers and Pharmacies are not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly, and the compounded medications offered through the Services are not manufactured by them. References to brand-name products are for identification only, and all other trademarks and brand names referenced are the property of their respective owners.
7. Results May Vary
Individual results vary and are not guaranteed. Weight loss depends on many factors, including adherence to your treatment plan, diet, physical activity, and individual health conditions. Any results described on the Services are not typical and should not be expected. SurpassMD does not guarantee any particular outcome.
8. Weight-Loss Consumer Bill of Rights
The following disclosures are provided in accordance with applicable weight-loss consumer protection laws, including Florida Statutes section 501.0575:
Rapid weight loss may cause serious health problems. Rapid weight loss means losing more than 1½ to 2 pounds per week, or more than 1 percent of body weight per week, after the second week of participation in a weight-loss program.
- Consult your personal physician before starting any weight-loss program.
- Only permanent lifestyle changes, such as making healthful food choices and increasing physical activity, promote long-term weight loss.
- The qualifications of the providers offering this program are available to you upon request.
As a weight-loss consumer, you also have the right to: (a) ask questions about the potential health risks of this program, its nutritional content, psychological support, and educational components, and have those questions answered; (b) receive an itemized statement of the actual or estimated price of the program, including extra products, services, supplements, examinations, and laboratory tests; (c) know the actual or estimated duration of the program; and (d) know the name, address, and qualifications of the dietitian or nutritionist who has reviewed and approved the program.
9. Questions
If you have questions about this information, contact us at care@surpassmd.com, or Gangotri46 Ventures LLC dba SurpassMD, 30 N Gould St, Ste R, Sheridan, WY 82801-6317. Always consult your Provider with medical questions.
© 2026 Gangotri46 Ventures LLC dba SurpassMD. All rights reserved.